EP1689354A4 - Linderung von katarakten, makuladegeneration und anderen augenerkrankungen - Google Patents

Linderung von katarakten, makuladegeneration und anderen augenerkrankungen

Info

Publication number
EP1689354A4
EP1689354A4 EP04812275A EP04812275A EP1689354A4 EP 1689354 A4 EP1689354 A4 EP 1689354A4 EP 04812275 A EP04812275 A EP 04812275A EP 04812275 A EP04812275 A EP 04812275A EP 1689354 A4 EP1689354 A4 EP 1689354A4
Authority
EP
European Patent Office
Prior art keywords
cataracts
amelioration
macular degeneration
ophthalmic diseases
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04812275A
Other languages
English (en)
French (fr)
Other versions
EP1689354A2 (de
Inventor
William L Matier
Ghanshyam Patil
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Othera Holding Inc
Original Assignee
Othera Holding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Othera Holding Inc filed Critical Othera Holding Inc
Publication of EP1689354A2 publication Critical patent/EP1689354A2/de
Publication of EP1689354A4 publication Critical patent/EP1689354A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
EP04812275A 2003-11-20 2004-11-22 Linderung von katarakten, makuladegeneration und anderen augenerkrankungen Withdrawn EP1689354A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52380303P 2003-11-20 2003-11-20
PCT/US2004/039716 WO2005055926A2 (en) 2003-11-20 2004-11-22 Amelioration of cataracts, macular degeneration and other ophthalmic diseases

Publications (2)

Publication Number Publication Date
EP1689354A2 EP1689354A2 (de) 2006-08-16
EP1689354A4 true EP1689354A4 (de) 2010-07-14

Family

ID=34676585

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04812275A Withdrawn EP1689354A4 (de) 2003-11-20 2004-11-22 Linderung von katarakten, makuladegeneration und anderen augenerkrankungen

Country Status (8)

Country Link
EP (1) EP1689354A4 (de)
JP (1) JP2007527417A (de)
KR (1) KR20070040326A (de)
CN (1) CN101102770A (de)
AU (1) AU2004296738A1 (de)
CA (1) CA2546053A1 (de)
IL (1) IL175498A0 (de)
WO (1) WO2005055926A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
EP1996195A4 (de) * 2006-02-22 2009-08-12 Othera Holding Inc Hydroxylamine und derivate zum hemmen der komplementaktivierung
WO2008101195A2 (en) * 2007-02-16 2008-08-21 Othera Holding, Inc. Drug resistance reversal in neoplastic disease
CN105998028A (zh) * 2007-02-22 2016-10-12 科尔比制药公司 羟胺化合物及其用法
WO2009070693A2 (en) * 2007-11-28 2009-06-04 Sirion Therapeutics, Inc Modulators of ocular oxidative stress
EP2080513A1 (de) 2008-01-16 2009-07-22 Schraermeyer, Ulrich, Prof. Dr. rer. nat Tetrahydropyridoether zur Behandlung von AMD
CN102988331B (zh) * 2012-05-31 2015-02-04 管孝君 2-巯基-3-丁醇用于制备抗晶状体混浊产品的用途
WO2015168347A1 (en) 2014-04-30 2015-11-05 The Johns Hopkins University Dendrimer compositions and their use in treatment of diseases of the eye
CN115350285A (zh) 2014-08-13 2022-11-18 约翰霍普金斯大学 树枝状聚合物到脑肿瘤的选择性传递
JP6509244B2 (ja) * 2014-10-31 2019-05-08 株式会社坪田ラボ 水晶体硬化抑制剤
US11160881B2 (en) 2017-04-27 2021-11-02 The Johns Hopkins University Dendrimer compositions for use in angiography
WO2018201124A1 (en) * 2017-04-28 2018-11-01 Case Western Reserve University Antioxidants for use in ophthalmic surgery
US11918657B2 (en) 2017-11-10 2024-03-05 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
IL293606A (en) 2019-12-04 2022-08-01 Ashvattha Therapeutics Inc Dendrimer preparations and methods of administering a drug to the eye

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0327263A1 (de) * 1988-01-29 1989-08-09 PROCTOR, Peter H. Haarwachstumanregung mit Nitroxyd und anderen Radikalen
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
WO2003096991A2 (en) * 2002-05-17 2003-11-27 Othera Pharmaceuticals, Inc. Amelioration of the development of cataracts and other opthalmic diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1447095A (en) * 1993-12-30 1995-07-17 Arcturus Pharmaceutical Corporation Methods for the treatment of the central nervous system or eye involving pathogenic oxidation pathways
ES2148469T3 (es) * 1994-11-15 2000-10-16 Moreno Paolini N-hidroxipiperidinas como agentes de barrido de radicales superoxido.
ATE428470T1 (de) * 2000-06-29 2009-05-15 Mei Co Ltd Heilmittel zur behandlung von erkrankungen des sehnervs
IT1320080B1 (it) * 2000-10-25 2003-11-18 Giuliani Spa Composizione per uso farmaceutico o dietetico.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352442A (en) * 1985-07-18 1994-10-04 Proctor Peter H Topical tempo
EP0327263A1 (de) * 1988-01-29 1989-08-09 PROCTOR, Peter H. Haarwachstumanregung mit Nitroxyd und anderen Radikalen
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
WO2003096991A2 (en) * 2002-05-17 2003-11-27 Othera Pharmaceuticals, Inc. Amelioration of the development of cataracts and other opthalmic diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EL-REMESSY AZZA B ET AL: "Neuroprotective effect of (-)DELTA9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: Involvement of peroxynitrite.", AMERICAN JOURNAL OF PATHOLOGY, vol. 163, no. 5, 1 November 2003 (2003-11-01), pages 1997 - 2008, XP002584345, ISSN: 0002-9440 *
WANG MIN ET AL: "Tempol, superoxide dismutase mimic, ameliorates light-induced retinal degeneration", RESEARCH COMMUNICATIONS IN MOLECULAR PATHOLOGY AND PHARMACOLOGY, PJD PUBLICATIONS LTD, US, vol. 89, no. 3, 1 September 1995 (1995-09-01), pages 291 - 305, XP009114398, ISSN: 1078-0297 *
WERMUTH C G ET AL: "The Practice of Medicinal Chemistry , DESIGNING PRODRUGS AND BIOPRECURSORS I: CARRIER PROGRUGS", PRACTICE OF MEDICINAL CHEMISTRY, XX, XX, 1 January 1996 (1996-01-01), pages 671 - 696, XP002290286 *
ZIGLER J SAMUEL JR ET AL: "Tempol-H inhibits opacification of lenses in organ culture.", FREE RADICAL BIOLOGY & MEDICINE, vol. 35, no. 10, 15 November 2003 (2003-11-15), pages 1194 - 1202, XP002584344, ISSN: 0891-5849 *

Also Published As

Publication number Publication date
WO2005055926A3 (en) 2006-12-07
AU2004296738A1 (en) 2005-06-23
WO2005055926A2 (en) 2005-06-23
KR20070040326A (ko) 2007-04-16
JP2007527417A (ja) 2007-09-27
IL175498A0 (en) 2008-04-13
CN101102770A (zh) 2008-01-09
EP1689354A2 (de) 2006-08-16
CA2546053A1 (en) 2005-06-23

Similar Documents

Publication Publication Date Title
EP1689397A4 (de) Linderung von makuladegeneration und anderen augenerkrankungen
EP1689354A4 (de) Linderung von katarakten, makuladegeneration und anderen augenerkrankungen
ZA200408449B (en) Amelioration of the development of cataracts and other opthalmic diseases
IL177284A0 (en) Management of ophthalmologic disorders, including macular degeneration
PL383268A1 (pl) Kompozycje oftalmiczne i sposoby leczenia oczu
IL191148A0 (en) Optical devices and methods for selective and conventional photocoagulation of the retinal pigment epithelium
EG24420A (en) Treatment of ophthalmic conditions
IL230241A (en) Retinal history and methods of using them to treat visual irregularities
IL173351A0 (en) Therapy of ocular disorders
EP1933751A4 (de) Intrastromale refraktive chirurgie durch induktion von formveränderungen in der hornhaut
EP1732484A4 (de) Ophthalmisches implantat zur behandlung von glaukom
EP1753445A4 (de) Behandlung von augenerkrankungen und augenleiden mit lantibiotischen zusammensetzungen
EP1796675A4 (de) Zusammensetzungen und verfahren zur behandlung von augenerkrankungen
AU2001260197A1 (en) Selective corneal aberrometry
EP1542664A4 (de) Verfahren und zusammensetzungen zur behandlung von makula- und retina-erkrankungen
GB0523961D0 (en) The treatment of ophthalmic diseases
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
EP1545555A4 (de) Zusammensetzungen und verfahren zur behandlung von epithel- und retinalgewebe-erkrankungen
EP2083841A4 (de) Behandlung für altersbedingte makuladegeneration und andere augenleiden
AU2003248565A1 (en) Disposable undergarment and methods of making, using and marketing same
ZA200605378B (en) Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration
GB0414772D0 (en) Ophthalmic eye preparation
PL378399A1 (pl) Zastosowanie genów z rodziny sgk do diagnozowania i terapii zaćmy i jaskry
IL175311A0 (en) Cytokine inhibitory drugs for treatment of macular degeneration
GB2403908B (en) Artificial cornea

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060620

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK YU

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/445 20060101AFI20070116BHEP

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OTHERA HOLDING, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 405/12 20060101ALI20100528BHEP

Ipc: C07D 401/12 20060101ALI20100528BHEP

Ipc: C07D 211/94 20060101ALI20100528BHEP

Ipc: A61K 9/00 20060101ALI20100528BHEP

Ipc: A61P 39/06 20060101ALI20100528BHEP

Ipc: A61P 27/12 20060101ALI20100528BHEP

Ipc: A61P 27/06 20060101ALI20100528BHEP

Ipc: A61P 27/02 20060101ALI20100528BHEP

Ipc: A61K 38/06 20060101ALI20100528BHEP

Ipc: A61K 45/06 20060101ALI20100528BHEP

Ipc: A61K 31/4525 20060101ALI20100528BHEP

Ipc: A61K 31/198 20060101ALI20100528BHEP

Ipc: A61K 31/145 20060101ALI20100528BHEP

Ipc: A61K 31/445 20060101AFI20070116BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100914